Blocking these interactions hasbeen extremely successful, with nine anti-PD1/PDL1 antibodies marketedfor 16 cancer conditions and many currently being trialed.3 Recently, there has been interest in the developmentof antibodies targeting co-stimulatory molecules to activate the immunesystem; such molecules include OX40, 4-1BB, and CD80/86. This evidence concerns the gene CD274 and cancer.